Evidence map›Paper›PMID 27537839›Full record

ArticlePloS one2016

Evaluation of a Salmonella Strain Lacking the Secondary Messenger C-di-GMP and RpoS as a Live Oral Vaccine.

Cristina Latasa, Maite Echeverz, Begoña García, Carmen Gil, Enrique García-Ona, Saioa Burgui, Noelia Casares, Sandra Hervás-Stubbs, Juan José Lasarte, Iñigo Lasa and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Molecular epidemiology ofAntimicrobial agents and chemotherapy · 2025
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Identification of Genetic Features for Attenuation of TwoFrontiers in veterinary science · 2019
    Article
  10. Review
  11. Vaccination against Salmonella Infection: the Mucosal Way.Microbiology and molecular biology reviews : MMBR · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Cristina LatasaLaboratory of Microbial Biofilms, Instituto de Agrobiotecnología (Idab), Universidad Pública de Navarra-CSIC-Gobierno de Navarra, Pamplona, Spain.
Maite EcheverzLaboratory of Microbial Biofilms, Instituto de Agrobiotecnología (Idab), Universidad Pública de Navarra-CSIC-Gobierno de Navarra, Pamplona, Spain.
Begoña GarcíaLaboratory of Microbial Biofilms, Instituto de Agrobiotecnología (Idab), Universidad Pública de Navarra-CSIC-Gobierno de Navarra, Pamplona, Spain.
Carmen GilLaboratory of Microbial Biofilms, Instituto de Agrobiotecnología (Idab), Universidad Pública de Navarra-CSIC-Gobierno de Navarra, Pamplona, Spain.
Enrique García-OnaLaboratory of Microbial Biofilms, Instituto de Agrobiotecnología (Idab), Universidad Pública de Navarra-CSIC-Gobierno de Navarra, Pamplona, Spain.
Saioa BurguiLaboratory of Microbial Biofilms, Instituto de Agrobiotecnología (Idab), Universidad Pública de Navarra-CSIC-Gobierno de Navarra, Pamplona, Spain.
Noelia CasaresProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Instituto de Investigación Sanitaria de Navarra (IdISNA), University of Navarra, Pamplona, Spain.
Sandra Hervás-StubbsProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Instituto de Investigación Sanitaria de Navarra (IdISNA), University of Navarra, Pamplona, Spain.
Juan José LasarteProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Instituto de Investigación Sanitaria de Navarra (IdISNA), University of Navarra, Pamplona, Spain.
Iñigo LasaLaboratory of Microbial Biofilms, Instituto de Agrobiotecnología (Idab), Universidad Pública de Navarra-CSIC-Gobierno de Navarra, Pamplona, Spain.
Cristina SolanoLaboratory of Microbial Biofilms, Instituto de Agrobiotecnología (Idab), Universidad Pública de Navarra-CSIC-Gobierno de Navarra, Pamplona, Spain.ORCID http://orcid.org/0000-0002-6207-1766
Universidad Publica de Navarra · ESNavarre Institute of Health Research · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salmonellosis is one of the most important bacterial zoonotic diseases transmitted through the consumption of contaminated food, with chicken and pig related products being key reservoirs of infection. Although numerous studies on animal vaccination have been performed in order to reduce Salmonella prevalence, there is still a need for an ideal vaccine. Here, with the aim of constructing a novel live attenuated Salmonella vaccine candidate, we firstly analyzed the impact of the absence of cyclic-di-GMP (c-di-GMP) in Salmonella virulence. C-di-GMP is an intracellular second messenger that controls a wide range of bacterial processes, including biofilm formation and synthesis of virulence factors, and also modulates the host innate immune response. Our results showed that a Salmonella multiple mutant in the twelve genes encoding diguanylate cyclase proteins that, as a consequence, cannot synthesize c-di-GMP, presents a moderate attenuation in a systemic murine infection model. An additional mutation of the rpoS gene resulted in a synergic attenuating effect that led to a highly attenuated strain, referred to as ΔXIII, immunogenic enough to protect mice against a lethal oral challenge of a S. Typhimurium virulent strain. ΔXIII immunogenicity relied on activation of both antibody and cell mediated immune responses characterized by the production of opsonizing antibodies and the induction of significant levels of IFN-γ, TNF-α, IL-2, IL-17 and IL-10. ΔXIII was unable to form a biofilm and did not survive under desiccation conditions, indicating that it could be easily eliminated from the environment. Moreover, ΔXIII shows DIVA features that allow differentiation of infected and vaccinated animals. Altogether, these results show ΔXIII as a safe and effective live DIVA vaccine.

Indexed as

Salmonella typhimuriumAdministration, OralAnimalsBacterial ProteinsCyclic GMPFemaleInterferon-gammaInterleukin-10Interleukin-17Interleukin-2MiceMice, Inbred BALB CSalmonella Infections, AnimalSalmonella VaccinesSigma FactorTumor Necrosis Factor-alphaBacterial Proteinsbis(3',5')-cyclic diguanylic acidCyclic GMPInterferon-gammaInterleukin-10Interleukin-17Interleukin-2Salmonella VaccinesSigma Factorsigma factor KatF protein, BacteriaTumor Necrosis Factor-alphaVaccines, Attenuated

Identifiers

PMID27537839
PMCPMC4990191
OpenAlexW2513053496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.